The Patent Finder
BI

Biogen Idec Ma Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Recorded as renamed to Biogen Ma Inc. (2015)

9 patents currently held

106 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.

The next term ends in Feb 2030. from the record

Of the 106 now held by other companies, 72 name Biogen Ma Inc. as their current owner, and 34 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Feb 2030
Next term end
9
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Chimeric Factor VIII Polypeptides and Uses Thereof US 11,370,827
The most cited patent in this portfolio, cited by 43 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Ends Jan 2034 · High confidence
Also notable
Bicyclic Aryl Sphingosine 1-Phosphate Analogs US 9,572,824
Cited by 17 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Ends Aug 2030 · High confidence
Also notable
Population Pharmacokinetics Tools and Uses Thereof US 10,325,687
Cited by 22 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2036.
Ends Jan 2036 · High confidence

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 108 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2028.
now held by Biogen Ma Inc.
Ends Feb 2028 · High confidence
Also notable
Cited by 101 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
now held by Biogen Ma Inc.
Ends Jan 2032 · High confidence
Also notable
Cited by 77 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Biogen Ma Inc.
Ends no later than Mar 2027 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 18, 2026
    The maintenance fee for Population Pharmacokinetics Tools and Uses Thereof (US 10,325,687) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 22, 2026
  • 4 terms have ended since Aug 22, 2026

What they patent

The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,696,307Methods for the Detection of JC Polyoma Virus
In force
 · Medium confidence
In forceMedium confidence
US 9,572,824Bicyclic Aryl Sphingosine 1-Phosphate Analogs
In force
 · High confidence
In forceHigh confidence
US 10,308,706Methods of Preventing and Removing Trisulfide Bonds
In force
 · Medium confidence
In forceMedium confidence
US 9,567,391JCV Neutralizing Antibodies
In force
 · High confidence
In forceHigh confidence
US 9,567,392JCV Neutralizing Antibodies
In force
 · High confidence
In forceHigh confidence
US 11,370,827Chimeric Factor VIII Polypeptides and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,623,088Factor VIII Polypeptide Formulations
In force
 · High confidence
In forceHigh confidence
US 10,188,732Methods and Compositions for Inactivating Enveloped Viruses
In force
 · High confidence
In forceHigh confidence
US 10,325,687Population Pharmacokinetics Tools and Uses Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 106 patents in force now held by others · 227 patents ended · 334 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited